Literature DB >> 2537875

Persistent productive HIV infection in EBV-transformed B lymphocytes.

V Tozzi1, S Britton, A Ehrnst, R Lenkei, O Strannegård.   

Abstract

The susceptibility to HIV infection of 14 B-cell lines established from five healthy HIV seronegative and from six HIV seropositive subjects by lymphocyte transformation with EBV and/or by lymphocyte cultivation with cyclosporin A was studied. Although the cell lines contained different proportions of CD4-positive cells, as shown by flow cytometry, all of them could be infected with the SF-2 strain of HIV. Infection was blocked by a monoclonal antibody directed against the viral attachment site of the CD4 molecule, even in a line that lacked demonstrable CD4 receptors. B-cell lines with high proportions of CD4-expressing cells produced HIV p24 antigen more rapidly and at higher concentrations than cell lines with low CD4 expression. Although HIV infection resulted in some cytopathic effects, it was possible to cultivate the infected cells for more than 8 months without refeeding the cultures with uninfected cells. Even in long-term cultures, there was a continuous production of infectious HIV, as detected by transfer of culture supernatants to other susceptible cell lines. The production of viral antigens was consistently more pronounced in the B-cell line with the highest CD4 positivity than it was in a permissive T-cell line (HUT-78) infected in the same manner. These results indicate that HIV can chronically and productively infect transformed B cells via interaction with CD4 molecules. Thus it is possible that B cells may constitute a source of infectious virus in HIV-infected EBV-positive individuals.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2537875     DOI: 10.1002/jmv.1890270105

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  8 in total

1.  Natural history of primary Epstein-Barr virus infection in children of mothers infected with human immunodeficiency virus type 1.

Authors:  H Jenson; K McIntosh; J Pitt; S Husak; M Tan; Y Bryson; K Easley; W Shearer
Journal:  J Infect Dis       Date:  1999-06       Impact factor: 5.226

2.  Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-kappa B activity.

Authors:  M L Hammarskjöld; M C Simurda
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

3.  CD40-Mediated induction of CD4 and CXCR4 on B lymphocytes correlates with restricted susceptibility to human immunodeficiency virus type 1 infection: potential role of B lymphocytes as a viral reservoir.

Authors:  S Moir; R Lapointe; A Malaspina; M Ostrowski; C E Cole; T W Chun; J Adelsberger; M Baseler; P Hwu; A S Fauci
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

4.  Complement receptor 2 mediates enhancement of human immunodeficiency virus 1 infection in Epstein-Barr virus-carrying B cells.

Authors:  M Tremblay; S Meloche; R P Sekaly; M A Wainberg
Journal:  J Exp Med       Date:  1990-05-01       Impact factor: 14.307

5.  Evaluation of human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T-lymphocyte responses utilizing B-lymphoblastoid cell lines transduced with the CD4 gene and infected with HIV-1.

Authors:  M J McElrath; M Rabin; M Hoffman; S Klucking; J V Garcia; P D Greenberg
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

6.  Human immunodeficiency virus induction of malignant transformation in human B lymphocytes.

Authors:  J Laurence; S M Astrin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

7.  EBV renders B cells susceptible to HIV-1 in humanized mice.

Authors:  Donal McHugh; Renier Myburgh; Nicole Caduff; Michael Spohn; Yik Lim Kok; Christian W Keller; Anita Murer; Bithi Chatterjee; Julia Rühl; Christine Engelmann; Obinna Chijioke; Isaak Quast; Mohaned Shilaih; Victoria P Strouvelle; Kathrin Neumann; Thomas Menter; Stephan Dirnhofer; Janice Kp Lam; Kwai F Hui; Simon Bredl; Erika Schlaepfer; Silvia Sorce; Andrea Zbinden; Riccarda Capaul; Jan D Lünemann; Adriano Aguzzi; Alan Ks Chiang; Werner Kempf; Alexandra Trkola; Karin J Metzner; Markus G Manz; Adam Grundhoff; Roberto F Speck; Christian Münz
Journal:  Life Sci Alliance       Date:  2020-06-23

8.  Mutations in the IGF-II pathway that confer resistance to lytic reovirus infection.

Authors:  Jinsong Sheng; Edward L Organ; Chuanming Hao; K Sam Wells; H Earl Ruley; Donald H Rubin
Journal:  BMC Cell Biol       Date:  2004-08-27       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.